BioPharmaPT
← All reports

Otsuka Holdings Co., Ltd. — Lytgobi EMA EPAR public assessment report (EMEA/H/C/005627, 2023)

Otsuka Holdings Co., Ltd. · 2023 · EMA EPAR public assessment report · company profile →

Report summary

Lytgobi (futibatinib) received a conditional marketing authorization recommendation for advanced cholangiocarcinoma with FGFR2 fusions/rearrangements in adults who progressed after prior systemic therapy. This was based on a single-arm Phase 2 study (TAS-120-101) showing a 41.7% objective response rate and 9.7 months median duration of response, addressing a significant unmet medical need. While effective, futibatinib exhibits a high incidence of adverse events, particularly hyperphosphatemia, and other toxicities like retinal disorders and hepatotoxicity, requiring dose modifications. Non-clinical studies revealed dose-dependent toxicities including ectopic mineralization and teratogenicity. Despite concerns regarding the single-arm trial's robustness, the CHMP concluded a positive benefit-risk balance.

Key findings — cited to the page

patients with nausea (any grade, SDG1)41 · p.87
patients with fatigue (any grade, SDG1)45 · p.87
patients with alopecia (any grade, SDG1)51 · p.87
patients with constipation (any grade, SDG1)54 · p.87
patients with diarrhea (any grade, SDG1)49 · p.87
patients with dry mouth (any grade, SDG1)45 · p.87
patients with treatment-related Grade >=3 AEs (SDG1)79 · p.85
patients with Grade >=3 AEs (SDG1)111 · p.85
patients with hyperphosphatemia (any grade, SDG1)124 · p.87
patients with Grade >=3 hyperphosphatemia (SDG1)39 · p.87
Grade ≥3 TREAEs: Stomatitis6.2 %Lytgobi (SDG1) · p.112
patients with dry skin (any grade, SDG1)40 · p.87

Source: Otsuka Holdings Co., Ltd. · License: EMA - reuse permitted with acknowledgement. Summary and findings are extracted from the published document; every figure cites its page. Informational only — not investment advice. Explore the Oncology library →

Otsuka Holdings Co., Ltd. — Lytgobi EMA EPAR public assessment report (EMEA/H/C/005627, 2023) — Summary & Key Findings | BioPharmaPT